KRAS and non-small cell lung carcinoma: Divarasib, a highly selective KRAS G12C inhibitor, has shown promising efficacy: in a phase I trial (NCT04449874) involving NSCLC patients, the ORR was 53% (95% CI: 39.9–66.7), and AEs were predominantly mild gastrointestinal AEs [126,127].